Welcome to our dedicated page for Cymabay Therapeu news (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on Cymabay Therapeu stock.
Cymabay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company advancing therapies for metabolic diseases and rare disorders. This page serves as the definitive source for official updates, including clinical trial milestones, regulatory developments, and strategic initiatives.
Investors and industry professionals will find curated press releases detailing CBAY’s progress in addressing high-need conditions through innovative drug development. Key updates cover Phase 1-3 trial results, FDA communications, and research collaborations within the biotech ecosystem.
All content is rigorously verified to ensure accuracy, with a focus on material developments impacting Cymabay’s scientific and operational trajectory. Bookmark this page for streamlined access to essential updates from the company’s Bay Area headquarters and global clinical sites.
CymaBay Therapeutics (NASDAQ: CBAY) has announced the publication of results from the ENHANCE phase 3 study of seladelpar, aimed at treating primary biliary cholangitis (PBC). The study demonstrated significant efficacy, with 78.2% of patients on 10 mg of seladelpar achieving the primary endpoint compared to 12.5% on placebo. Key secondary endpoints also showed promising results, including improvements in alkaline phosphatase levels and patient-reported pruritus. There were no adverse endpoints reported. Looking ahead, seladelpar is undergoing further evaluation in the RESPONSE phase 3 registration study, with results expected in Q3 2023, and the ASSURE long-term study to provide additional safety and efficacy data.
FAQ
What is the market cap of Cymabay Therapeu (CBAY)?
